€136.05
0.62%
Xetra, Oct 05, 05:35 pm CEST. Closed.
ISIN
DE0006599905
Symbol
MRK
Index

Merck Target price 2026 - Analyst rating & recommendation

Merck Classifications & Recommendation

Buy
55%
Hold
45%

Merck Price Target

Target Price €157.08
Price €136.05
Potential 15.46%
Number of Estimates 18
18 Analysts have issued a price target Merck 2027 . The average Merck target price is €157.08. This is 15.46% higher than the current stock price. The highest price target is €187.95 38.15% , the lowest is €136.35 0.22% .
A rating was issued by 22 analysts: 12 Analysts recommend Merck to buy, 10 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2027 of 15.46% . Most analysts recommend the Merck stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion € 21.10 21.67
0.26% 2.69%
EBITDA Margin 22.69% 28.35%
2.67% 24.97%
Net Margin 12.36% 16.97%
5.85% 37.31%

20 Analysts have issued a sales forecast Merck 2026 . The average Merck sales estimate is

€21.7b
unlock
. This is
2.53% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€22.9b 8.11%
unlock
, the lowest is
€20.7b 2.25%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 €21.1b 0.26%
2026
€21.7b 2.69%
unlock
2027
€22.9b 5.57%
unlock
2028
€24.1b 5.38%
unlock
2029
€24.9b 3.25%
unlock
2030
€26.3b 5.54%
unlock
2031
€27.5b 4.85%
unlock
2032
€29.0b 5.15%
unlock
2033
€30.4b 5.09%
unlock

18 Analysts have issued an Merck EBITDA forecast 2026. The average Merck EBITDA estimate is

€6.1b
unlock
. This is
5.82% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€6.6b 13.93%
unlock
, the lowest is
€5.5b 4.60%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 €4.8b 2.92%
2026
€6.1b 28.35%
unlock
2027
€6.5b 6.46%
unlock
2028
€7.1b 7.84%
unlock
2029
€7.7b 9.30%
unlock
2030
€8.3b 7.02%
unlock
2031
€8.9b 8.44%
unlock
2032
€9.5b 6.08%
unlock
2033
€10.1b 6.22%
unlock

EBITDA Margin

2025 22.69% 2.67%
2026
28.35% 24.97%
unlock
2027
28.59% 0.85%
unlock
2028
29.26% 2.34%
unlock
2029
30.98% 5.88%
unlock
2030
31.41% 1.39%
unlock
2031
32.48% 3.41%
unlock
2032
32.77% 0.89%
unlock
2033
33.12% 1.07%
unlock

20 Merck Analysts have issued a net profit forecast 2026. The average Merck net profit estimate is

€3.7b
unlock
. This is
55.15% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€4.0b 68.74%
unlock
, the lowest is
€3.4b 41.49%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 €2.6b 6.09%
2026
€3.7b 40.99%
unlock
2027
€3.8b 3.67%
unlock
2028
€4.3b 12.12%
unlock
2029
€4.7b 9.71%
unlock
2030
€5.1b 9.20%
unlock
2031
€5.9b 16.08%
unlock
2032
€6.4b 8.23%
unlock
2033
€7.0b 8.99%
unlock

Net Margin

2025 12.36% 5.85%
2026
16.97% 37.31%
unlock
2027
16.66% 1.83%
unlock
2028
17.73% 6.42%
unlock
2029
18.84% 6.26%
unlock
2030
19.49% 3.45%
unlock
2031
21.58% 10.72%
unlock
2032
22.21% 2.92%
unlock
2033
23.03% 3.69%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share € 6.00 8.46
6.10% 41.00%
P/E 16.19
EV/Sales 3.12

20 Analysts have issued a Merck forecast for earnings per share. The average Merck EPS is

€8.46
unlock
. This is
55.23% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
€9.20 68.81%
unlock
, the lowest is
€7.71 41.47%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 €6.00 6.10%
2026
€8.46 41.00%
unlock
2027
€8.77 3.66%
unlock
2028
€9.83 12.09%
unlock
2029
€10.78 9.66%
unlock
2030
€11.78 9.28%
unlock
2031
€13.67 16.04%
unlock
2032
€14.79 8.19%
unlock
2033
€16.12 8.99%
unlock

P/E ratio

Current 25.12 55.05%
2026
16.19 35.55%
unlock
2027
15.62 3.52%
unlock
2028
13.93 10.82%
unlock
2029
12.69 8.90%
unlock
2030
11.62 8.43%
unlock
2031
10.01 13.86%
unlock
2032
9.25 7.59%
unlock
2033
8.49 8.22%
unlock

Based on analysts' sales estimates for 2026, the Merck stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.20 25.98%
2026
3.12 2.51%
unlock
2027
2.96 5.27%
unlock
2028
2.80 5.11%
unlock
2029
2.72 3.15%
unlock
2030
2.57 5.25%
unlock
2031
2.45 4.63%
unlock
2032
2.33 4.89%
unlock
2033
2.22 4.84%
unlock

P/S ratio

Current 2.77 27.10%
2026
2.70 2.46%
unlock
2027
2.56 5.27%
unlock
2028
2.43 5.10%
unlock
2029
2.35 3.15%
unlock
2030
2.23 5.25%
unlock
2031
2.12 4.63%
unlock
2032
2.02 4.90%
unlock
2033
1.92 4.85%
unlock

Current Merck Upgrades & Downgrades

Analyst Rating Action Date
ROTHSCHILD & CO REDBURN
Buy
➜
Buy
Unchanged Sep 23 2026
DAY BY DAY
Buy
➜
Hold
Downgrade Sep 21 2026
BAADER EUROPE / ALPHAVALUE
Buy
➜
Buy
Unchanged Sep 10 2026
EQUITA SIM
Hold
➜
Hold
Unchanged Sep 04 2026
JEFFERIES
Hold
➜
Hold
Unchanged Sep 03 2026
BNP PARIBAS
Outperform
➜
Outperform
Unchanged Aug 31 2026
LANDESBANK BADEN-WUERTTEMBERG
Buy
➜
Buy
Unchanged Aug 26 2026
Analyst Rating Date
Unchanged
ROTHSCHILD & CO REDBURN:
Buy
➜
Buy
Sep 23 2026
Downgrade
DAY BY DAY:
Buy
➜
Hold
Sep 21 2026
Unchanged
BAADER EUROPE / ALPHAVALUE:
Buy
➜
Buy
Sep 10 2026
Unchanged
EQUITA SIM:
Hold
➜
Hold
Sep 04 2026
Unchanged
JEFFERIES:
Hold
➜
Hold
Sep 03 2026
Unchanged
BNP PARIBAS:
Outperform
➜
Outperform
Aug 31 2026
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Buy
➜
Buy
Aug 26 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today